| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Arine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $66.04M | Series C | 6/24/2025 | $30M | $494.87M | $15.42 | Town Hall Ventures, Kaiser Permanente Ventures | ||||
 | Edison Scientific | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.89M | Series Seed | 12/18/2025 | $51M | $244.55M | $16.59 | Triatomic Capital, Spark Capital, Pillar, Susa Ventures, Striker Venture Partners, Hawktail, Olive Capital | ||||
 | Gravie | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $379M | Series G | 6/5/2026 | $200M | $367.42M | $1.28 | Aberdare Ventures, FirstMark Capital, K2 HealthVentures | ||||
 | Human Longevity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $91.95M | Series B-1 | 8/21/2024 | $32M | $185.79M | $0.31 | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust | ||||
 | Kumquat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.92M | Series A-2 | 7/28/2021 | $30M | $494.98M | $10.32 | Undisclosed Investors | ||||
 | Mesh Optical Technologies | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $50M | Series A-1 | 2/17/2026 | $37.93M | $253.44M | $16.17 | Thrive Capital, Also Capital, Banner Ventures | ||||
 | Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.76M | Series C | 6/30/2023 | $64M | $308.05M | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | ||||
 | PineTree Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $87.5M | Series B | 10/28/2025 | $47M | $336.28M | $12.00 | DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atinum Investment, S&S Investment, SJ Investment Partners, Smilegate Investment, Gauss Capital Management, Korea Investment Partners, SV Investment | ||||
 | Syncromune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.01M | Series A-1 | 8/21/2025 | $99.85M | $254.93M | $3.43 | Wasatch Equity Partners | ||||
 | Timberlyne Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $9.88M | Series A | 1/9/2025 | $9.37M | $137.37M | $3.64 | Abingworth, Bain Capital Life Sciences, Venrock, Boyu Capital, Lilly Asia Ventures, Braidwell, 3H Health Investment | ||||
 | Tortugas Neuroscience | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $106M | Series A1 | 4/21/2026 | $33.84M | $273.53M | $7.49 | Cure Ventures, The Column Group, AN Venture Partners | ||||
 | Virtual Incision | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.09M | Series B | 9/17/2026 | $80.14M | $103.13M | $0.13 | Undisclosed Investors | ||||
 | Aerin Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $172.7M | Series G | 1/13/2025 | $32.82M | $342.42M | $1.17 | KCK MedTech, Questa Capital, OrbiMed, Ally Bridge Group, Ares Capital | ||||
 | Engrail Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $215.08M | Series B-4 | 4/7/2025 | $10M | $275.98M | $1.06 | Undisclosed Investors | ||||
 | Flare Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $290.35M | Series C | 6/30/2026 | $85M | $188.49M | $0.37 | Third Rock Ventures, Nextech Invest, Pfizer, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management | ||||
 | Honeycomb Insurance Services | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $93.54M | Series B-2 | 6/4/2026 | $35.8M | $432.12M | $6.37 | Zeev Ventures, Ibex Investors, Peakline Partners, Alpha Partners, Meitar Partners, Practical Venture Capital, Harris Barton | ||||
 | IntelyCare | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $237.55M | Series D | 10/29/2026 | $6M | $51.7M | $0.54 | -- | ||||
 | KSQ Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $417.49M | Series D-1 | 10/24/2025 | $160.03M | $486.98M | $2.65 | Undisclosed Investors | ||||
 | Lycia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $278.31M | Series D | 6/10/2026 | $75M | $386M | $9.21 | -- | ||||
 | Musely | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $28.08M | Series B | 9/12/2014 | $20M | $117.1M | $12.56 | SharesPost and several undisclosed investors | ||||
 | NowRx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $114.11M | Series C | 10/7/2021 | $74.03M | $334.19M | $10.50 | Undisclosed Investors | ||||
 | Two Chairs | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $106.66K | -- | 1 | Not available | -- | -- | $92.39M | Series C | 4/16/2024 | $40M | $250.37M | $8.00 | Amplo, Fifth Down Capital | ||||
 | AiTA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25.63M | Series C | 1/14/2025 | $10M | $317.19M | $5.05 | Undisclosed Investors | ||||
 | Bluejay Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $242.24M | Series C-1 | 5/9/2024 | $1.14M | $371.77M | $6.53 | Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital | ||||